

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

18528.642

APPLICATION NO.

10/643,681

APPLICANTS

Orville G. KOLTERMAN *et al.*

FILING DATE

August 18, 2003

GROUP

~~1646~~

1639

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
<i>ML</i>	AA1	5,124,314	6/1992	Cooper			
	AB1	5,166,192	11/1992	Mathias			
	AC1	5,175,145	12/1992	Cooper			
	AD1	5,187,154	2/1993	Phillips <i>et al.</i>			
	AE1	5,234,906	8/1993	Young <i>et al.</i>			
	AF1	5,260,275	11/1993	Cooper <i>et al.</i>			
	AG1	5,264,372	11/1993	Beaumont <i>et al.</i>			
	AH1	5,266,561	11/1993	Cooper <i>et al.</i>			
	AI1	5,281,581	1/1994	Cooper <i>et al.</i>			
	AJ1	5,367,052	11/1994	Cooper <i>et al.</i>			
	AK1	5,376,638	12/1994	Young <i>et al.</i>			
	AL1	5,580,953	12/1996	Albrecht <i>et al.</i>			
	AM1	5,686,411	11/1997	Gaeta <i>et al.</i>			
<i>ML</i>	AN1	6,114,304	9/2000	Kolterman <i>et al.</i>			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
<i>ML</i>	AN1	0 289 287 A2	11/1988	Europe			Yes No
	AO1	93/10146	5/1993	PCT			Yes No
	AP1	93/10147	5/1993	PCT			Yes No
<i>ML</i>	AQ1	92/20367	11/1992	PCT			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>ML</i>	ARI	Alam <i>et al.</i> , "Selective Antagonism of Calcitonin-induced Osteoclastic Quiescence (Q Effect) by Human Calcitonin Gene-Related Peptide-(Val <sup>8</sup> Phe <sup>37</sup> )", <i>Biochem. Biophys. Res. Commun.</i> , 179(1):134-139 (1991)
-----------	-----	--


EXAMINER

DATE CONSIDERED

12/7/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 18528.642	APPLICATION NO. 10/643,681
		APPLICANTS Orville G. KOLTERMAN <i>et al.</i>	
		FILING DATE August 18, 2003	GROUP <del>1646</del> 1639
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AA2	Amara <i>et al.</i> , "Expression in Brain of a Messenger RNA Encoding a Novel Neuropeptide Homologous to Calcitonin Gene-Related Peptide", <u>Science</u> , 229:1094-1097 (1985)	
	AB2	Brain <i>et al.</i> , "Amylin Amide, Which is Structurally Similar to Calcitonin Gene-Related Peptide (CGRP), Stimulates Increased Blood Flow In Vivo", <u>Eur. J. Pharmacol.</u> , 183:221 (1990)	
	AC2	Brener <i>et al.</i> , "Regulation of the Gastric Emptying of Glucose", <u>Gastroenterology</u> , 85:76-82 (1983)	
	AD2	Briner <i>et al.</i> , "Tageszeitliche Schwankungen der Glukose-toleranz bei Diabetikern und Nichtdiabetiker, unter besonderer Berücksichtigung der Magenentleerung", <u>Schweiz Rundsh Med. Prax.</u> , 68:1666-1672 (1979)	
	AE2	Broderick <i>et al.</i> , "Human and Rat Amylin have no Effects on Insulin Secretion in Isolated Rat Pancreatic Islets", <u>Biochem. Biophys. Res. Comm.</u> , 177:932-938 (1991)	
	AF2	Camilleri & Malagelada, "Abnormal Intestinal Motility in Diabetes with the Gastroparesis Syndrome", <u>European Journal of Clinical Investigation</u> , 14:420-427 (1984)	
	AG2	Campbell <i>et al.</i> , "Gastric Emptying in Diabetic Autonomic Neuropathy", <u>Gut</u> , 18:462-467 (1977)	
	AH2	Cavallo-Perin <i>et al.</i> , "Gastric Emptying of Liquids and Solids Evaluated by Acetaminophen Test in Diabetic Patients with and without Autonomic Neuropathy", <u>European Review for Medical &amp; Pharmacological Sciences</u> , XIII:205-209 (1991)	
	AI2	Chance <i>et al.</i> , "Anorexia Following the Intrahypothalamic Administration of Amylin", <u>Brain Research</u> , 539:352-354 (1991)	
	AJ2	Chantry <i>et al.</i> , "Cross-reactivity of Amylin with Calcitonin-Gene-Related Peptide Binding Sites in Rat Liver and Skeletal Muscle Membranes", <u>Biochem. J.</u> , 277:139-143 (1991)	
	AK2	Clouse and Lustman, "Gastrointestinal Symptoms in Diabetic Patients: Lack of Association with Neuropathy", <u>The American Journal of Gastroenterology</u> , 84(8):868-872 (1989)	
	AL2	Cohen <i>et al.</i> , <u>The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis</u> , pp. 11-52, Millipore Corporation (1989)	
EXAMINER 		DATE CONSIDERED 12/7/04	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. * Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			

FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

18528.642

APPLICATION NO.

10/643,681

APPLICANTS

Orville G. KOLTERMAN *et al.*

FILING DATE


August 18, 2003

GROUP

1646 1639

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AA3

 Cooper *et al.*, "Purification and Characterization of a Peptide from Amyloid-Rich Pancreases of Type 2 Diabetic Patients", Proc. Natl. Acad. Sci. USA, 84:8628-8632 (1987)

AB3

Cooper *et al.*, "Amylin Found in Amyloid Deposits in Human Type 2 Diabetes Mellitus May be a Hormone that Regulates Glycogen Metabolism Skeletal Muscle", Proc. Natl. Acad. Sci. USA, 85:7763-7766 (1988)

AC3

Cooper *et al.*, "The Amylin Superfamily: A Novel Grouping of Biologically Active Polypeptides Related to the Insulin A-Chain", Progress in Growth Factor Research, 1:99-105 (1989)

AD3

Cooper *et al.*, "Amylin and the Amylin Gene: Structure, Function and Relationship to Islet Amyloid and to Diabetes Mellitus", Biochem. Biophysica Acta, 1014:247-258 (1989)

AE3

Cooper *et al.*, "Amylin Action: Physiologic Basis and Pathologic Correlations", Diabetes, 497-500 (1991)

AF3

Cotroneo *et al.*, "Gastric Emptying Rate and Hormonal Response in Type II Diabetics", Diabetes Res., 17:99-104 (1991)

AG3

Daniel *et al.*, "Use of Glucagon in the Treatment of Acute Diverticulitis", Br. Med. J., 3:720 (1974)

AH3

Dao *et al.*, "Lack of Modulation of Gastric Emptying by Acute Hyperglycemia in Type 2 Diabetes Mellitus", Gastroenterology, 98:A342 (1990)

AI3

Deems *et al.*, "Amylin or CGRP (-37) Fragments Reverse Amylin-Induced Inhibition of <sup>14</sup>C-Glycogen Accumulation", Biochem. Biophys. Res. Comm., 181(1):116-120 (1991)


AJ3

Eisenberg *et al.*, "Synchronous Gastric Motor and Secretory Activity in Normal and Diabetic Dogs: The importance of Variation in Blood Sugar Levels", Bulletin de la Societe Internationale de Chirurgie, 3:191-198 (1972)

AK3

Feldman *et al.*, "Abnormal Gastric Function in Longstanding, Insulin-Dependent Diabetic Patients", Gastroenterology, 77:12-17 (1979)

AL3

 Feldman *et al.*, "Disorders of Gastrointestinal Motility Associated with Diabetes Mellitus", Ann. Int. Med., 98:378-384 (1983)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.

FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

18528.642

APPLICATION NO.

10/643,681

APPLICANTS

Orville G. KOLTERMAN *et al.*

FILING DATE

August 18, 2003

GROUP

~~1646~~ 1639

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AA4

Feldman *et al.*, "Gastric Emptying of Solid Radiopaque Markers: Studies in Healthy Subjects and Diabetic Patients", Gastroenterology, 87:895-902 (1984)

AB4

Follett *et al.*, "Effect of Amylin on Insulin Receptor Kinase Activity *In Vivo* in the Rat", Clinical Research, 39(1):39A (1991)

AC4

Forster and Dockray, "Immunoneutralization suggests that calcitonin gene related peptide regulates gastric emptying in the rat", Neurosci. Lett., 131:5-7 (1991)

AD4

Franken *et al.*, "The Use of Glucagon in Hydrostatic Reduction of Intussusception: A Double-Blind Study of 30 Patients", Radiology, 146:687 (1983)

AE4

Fraser *et al.*, "Hyperglycaemia slows gastric emptying in Type 1 (insulin-dependent) diabetes mellitus", Diabetologia, 33:675-680 (1990)

AF4

Fraser *et al.*, "Hyperglycaemia Stimulates Pyloric Motility in Normal Subjects", Gut, 32:475-478 (1991)

AG4

Fraser *et al.*, "Effect of Insulin-Induced Hypoglycaemia in Antral, Pyloric and Duodenal Motility in Fasting Subjects", Clin. Sci., 81:281-285 (1991)

AH4

Frontoni *et al.*, "In Vivo Insulin Resistance Induced by Amylin Primarily Through Inhibition of Insulin-Stimulated Glycogen Synthesis in Skeletal Muscle", Diabetes, 40:568-573 (1991)

AI4

Gaber *et al.*, "Changes in Gastric Emptying in Recipients of Successful Combined Pancreas-Kidney Transplants", Dig. Dis., 9:437-443 (1991)

AJ4

Galeazza *et al.*, "Islet Amyloid Polypeptide (IAPP) Competes for Two Binding Sites of CGRP", Peptides, 12:585-591 (1991)

AK4

Gardiner *et al.*, "Antagonistic Effect of Human  $\alpha$ -Calcitonin Gene-related Peptide (8-37) on regional Hemodynamic Actions of Rat Islet Amyloid Polypeptide in Conscious Long-Evans Rats", Diabetes, 40:948-951 (1991)

AL4

Gedulin *et al.*, "Amylin Secretion from the Perfused Pancreas: Dissociation from Insulin and Abnormal Elevation in Insulin-Resistant Diabetic Rats", Biochem. Biophys. Res. Commun., 180(2):782-789 (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO.	APPLICATION NO.
		18528.642	10/643,681
		APPLICANTS	
		Orville G. KOLTERMAN <i>et al.</i>	
		FILING DATE	GROUP
		August 18, 2003	1646 1639
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
MC	AA5	Gilbey <i>et al.</i> , "Amylin Lowers Serum Calcium in Pagets Bond Disease Further Evidence for a Role in Calcium Metabolism", <u>J. Bone Mineral Res.</u> , S293 (1991)	
	AB5	Gill <i>et al.</i> , "Effects of Ciglitazone on Endogenous Plasma Islet Amyloid Polypeptide and Insulin Sensitivity in Obese-Diabetic Viable Yellow Mice", <u>Life Sciences</u> , 48:703-710 (1991)	
	AC5	Glauser <i>et al.</i> , "Intravenous Glucagon in the Management of Esophageal Food Obstruction", <u>J. Am. Coll. Emergency Physns.</u> , 8:228 (1979)	
	AD5	Gomez-Foix <i>et al.</i> , "Anti-Insulin Effects of Amylin and Calcitonin-Gen-Related Peptide on Hepatic Glycogenmetabolism", <u>Biochem. J.</u> , 276:607-610 (1991)	
	AE5	<u>Goodman and Gilman's The Pharmacological Basis of Therapeutics</u> , Chapter 38, Pergamon Press, Eighth Edition (1990)	
	AF5	Hartter <i>et al.</i> , "Basal and Stimulated Plasma Levels of Pancreatic Amylin Indicate its Co-Secretion with Insulin in Humans", <u>Diabetologia</u> , 34:52-54 (1991)	
	AG5	Horowitz <i>et al.</i> , "Gastric and Oesophageal Emptying in Patients with Type 2 (Non-Insulin-Dependent) Diabetes Mellitus", <u>Diabetologia</u> , 32:151-159 (1989)	
	AH5	Horowitz <i>et al.</i> , "Disordered Gastric Motor Function in Diabetes Mellitus", <u>Scand. J. Gastroenterol.</u> , 26:673-684 (1991)	
	AI5	Horowitz <i>et al.</i> , "Relationships Between Oesophageal Transit and Solid and Liquid Gastric Emptying in Diabetes Mellitus", <u>Eur. J. Nucl. Med.</u> , 18:229-234 (1991)	
	AJ5	Horowitz <i>et al.</i> , "Relationship Between Oral Glucose Tolerance and Gastric Emptying in Normal Healthy Subjects", <u>Diabetologia</u> , 36:857-862 (1993)	
	AK5	Horowitz <i>et al.</i> , "Disordered Gastric Motor Function in Diabetes Mellitus", <u>Diabetologia</u> , 37:543-551 (1994)	
MC	AL5	Huang <i>et al.</i> , "Hyperamylinemia, Hyperinsulinemia, and Insulin Resistance in Genetically Obese LA/N- <i>cp</i> Rats", <u>Hypertension</u> , 19:I-101-I-109 (1992)	
EXAMINER		DATE CONSIDERED	
		12/7/04	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			
* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			

FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

18528.642

APPLICATION NO.

10/643,681

APPLICANTS

Orville G. KOLTERMAN *et al.*

FILING DATE

August 18, 2003

GROUP

1646 1430

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AA6

"Introduction to Cleavage Techniques", Strategies in Peptides Synthesis, Applied Biosystems, Inc. (1990)

AB6

Isal *et al.*, "Gastric Emptying of Solid Radiopaque Markers in Diabetic Patients", Gastroenterology, 88:1094 (1985)

AC6

Janssens *et al.*, "Improvement of Gastric Emptying in Diabetic Gastroparesis by Erythromycin", N. Engl. J. Med., 322:1028-1031 (1990)

AD6

Jonderko *et al.*, "Calcitonin Suppresses Gastric Emptying of a Radiolabelled Solid Meal in Humans", Br. J. Clin. Pharmacol., 24:103-105 (1987)

AE6

Jonderko *et al.*, "Effect of Calcitonin on Gastric Emptying", Digestion, 40:191-196 (1988)

AF6

Jonderko, "Effect of Calcitonin on Gastric Emptying in Patients with an Active Duodenal Ulcer", Gut, 30:430-435 (1989)

AG6

Kanatsuka *et al.*, "Secretion of Islet Amyloid Polypeptide in Response to Glucose", FEBS Lett., 259(1):199-201 (1989)

AH6

Katsoulis *et al.*, "Effects of Calcitonin Gene Related Peptides (CGRP), Calcitonin (CT) and Islet Amyloid Polypeptide (IAPP) on Gastric Motility of Guinea Pig and Rat", Regul. Pept., 26:77 (1989)

AI6

Keshavarzian *et al.*, "Gastric Emptying in Patients with Insulin-Requiring Diabetes Mellitus", Am. J. Gastroent., 82:29-35 (1987)

AJ6

Koda *et al.*, "Amylin Concentrations and Glucose Control", The Lancet, 339:1179-1180 (1992)

AK6

Kolterman *et al.*, "Infusion of Amylin Agonist, Reduces Postprandial Hyperglycemia in Subjects with Type I Diabetes (IDDM)", Clinical Research, 42(1):87A (1994)

AL6

Kong *et al.*, "Infusion of Pramlintide, a Human Amylin Analogue, Delays Gastric Emptying in Men with IDDM", Diabetologia, 40:82-88 (1997)

EXAMINER

DATE CONSIDERED

12/4/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.

FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

18528.642

APPLICATION NO.

10/643,681

APPLICANTS

Orville G. KOLTERMAN *et al.*

FILING DATE

August 18, 2003

GROUP

1646 1639

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

ML

AA7

Koopmans *et al.*, "Amylin Induced *In Vivo* Insulin Resistance in Conscious Rats: The Liver is More Sensitive to Amylin than Peripheral Tissues", Diabetologia, 34:218-224 (1991)

AB7

Leighton and Cooper, "Pancreatic Amylin and Calcitonin Gene-Related Peptide Cause Resistance to Insulin in Skeletal Muscle *In Vitro*", Nature, 335:632-635 (1988)

AC7

Lenz, "Calcitonin and CGRP Inhibit Gastrointestinal Transit Via Distinct Neuronal Pathways", Am. J. Physiol. Soc'y, G920-G924 (1988)

AD7

Lin *et al.*, "Gastric Emptying of Solid Meal in Diabetic Patients", Nippon Shokakigyo Gakkai Zasshi, 84:1-5 (1987)

AE7

Loo *et al.*, "Gastric Emptying in Patients with Diabetes Mellitus", Gastroenterology, 86:485-494 (1984)

AF7

Lupien and Young, "No Measurable Effect of Amylin on Lipolysis in Either White or Brown Isolated Adipocytes from Rats", Diabetes Nutrition and Metabolism - Clinical and Experimental, 6:13-18 (1993)

AG7

MacGregor *et al.*, "The Effect of Acute Hyperglycemia on Gastric Emptying in Man", Gastroenterology, 70:190-196 (1976)

AH7

McCallum *et al.*, "Definition of a Gastric Emptying Abnormality in Patients with Anorexia Nervosa", Digestive Diseases and Sciences, 30(8):713-722 (1985)

AI7

Mecklenbeck *et al.*, "Gastric Emptying in Diabetic Neuropathy: Two Different Forms of Disturbed Kinetics", Euro. J. Nucl. Med., 18:FP-3H3-1 (1991)

AJ7

Moberg & Carlberger, "Gastric Emptying in Healthy Subjects and in Patients with Various Malabsorptive States", Scand. J. Gastroent., 9:17-21(1973)

AK7

Molina *et al.*, "Induction of Insulin Resistance *In Vivo* by Amylin and Calcitonin Gene-Related Peptide", Diabetes, 39:260-265 (1990)

AL7




Moore and Rink, "Amylin Activates Adenylyl Cyclase in Rat Soleus Muscle", Diabetes, 42:5, 821 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



\* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		18528.642	10/643,681
		APPLICANTS	
		Orville G. KOLTERMAN <i>et al.</i>	
		FILING DATE	GROUP
		August 18, 2003	1646 1639
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AA8	Moore <i>et al.</i> , "Co-Secretion of Amylin and Insulin From Cultured Islet $\beta$ -Cells: Modulation by Nutrient Secretagogues, Islet Hormones and Hypoglycemic Agents", <u>Biochem. Biophys. Res. Commun.</u> , 179(1):1-9 (1991)	
	AB8	Nagai <i>et al.</i> , "A Case of Diabetic Neuropathy Accompanied by Relapsing Paralytic Ileus Due to Omeprazole Administration", <u>J. Japan. Diab. Soc.</u> , 36(9):733-739 (1993)	
	AC8	Nakanome <i>et al.</i> , <u>Tohoku J. Exp. Med.</u> , 139:205-215 (1983)	
	AD8	Nowak <i>et al.</i> , "Evidence for Accelerated Gastric Emptying in Asymptomatic Patients with Insulin-Dependent Diabetes Mellitus", <u>Gastroenterology</u> , 98:A378 (1990)	
	AE8	Ogawa <i>et al.</i> , "Amylin Secretion from the Rat Pancreas and its Selective Loss after Streptozotocin Treatment", <u>J. Clin. Invest.</u> , 85:973-976 (1990)	
	AF8	Ohsawa <i>et al.</i> , "Islet Amyloid Polypeptide Inhibits Glucose-Stimulated Insulin Secretion from Isolated Rat Pancreatic Islets", <u>Biochem. Biophys. Res. Commun.</u> , 160(2):961-967 (1989)	
	AG8	Pehling <i>et al.</i> , "Abnormal Meal Carbohydrate Disposition in Insulin-Dependent Diabetes", <u>J. Clin. Invest.</u> , 74:985-991 (1984)	
	AH8	Phillips <i>et al.</i> , "Rapid Gastric Emptying in Patients with Early Non-Insulin-Dependent Diabetes Mellitus", <u>N. Eng. J. Med.</u> , 10:130-131 (1991)	
	AI8	Phillips <i>et al.</i> , "Rapid Gastric Emptying of an Oral Glucose Solution in Type 2 Diabetes Mellitus", <u>J. Nucl. Med.</u> , 33:1496-1500 (1992)	
	AJ8	Phillips <i>et al.</i> , "Reduced Postprandial Blood Glucose Levels in Recently Diagnosed Non-Insulin-Dependent Diabetics Secondary to Pharmacologically Induced Delayed Gastric Emptying", <u>Digestive Diseases and Sciences</u> , 38:51-58 (1993)	
	AK8	Plourde <i>et al.</i> , "CGRP 8027 Blocks the Inhibition of Gastric Emptying Induced by Intravenous Injection of $\alpha$ -CGRP in Rats", <u>Life Sciences</u> , 52:857-862 (1993)	
	AL8	Raybould <i>et al.</i> , "Central Nervous System Action of Calcitonin Gene-Related Peptide to Inhibit Gastric Emptying in the Conscious Rat", <u>Peptides</u> , 9:735-739 (1988)	
EXAMINER		DATE CONSIDERED	
		12/7/04	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. * Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO.	APPLICATION NO.
		18528.642	10/643,681
		APPLICANTS	
		Orville G. KOLTERMAN <i>et al.</i>	
		FILING DATE	GROUP
		August 18, 2003	<del>1646</del> 1639
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
AA9		"Remington's Pharmaceutical Sciences", Alfonso Gennaro, Editor, Mack Publishing Company, 18 <sup>th</sup> Edition, TABLE OF CONTENTS	
AB9		Roden <i>et al.</i> , "Effects of Islet Amyloid Polypeptide on Hepatic Insulin Resistance and Glucose Production in the Isolated Perfused Rat Liver", <u>Diabetologia</u> , 35:116-120 (1992)	
AC9		Saltzman and McCallum, "Diabetes and the Stomach", <u>Yale J. Biol. Med.</u> , 56:179-187 (1983)	
AD9		Sambrook <i>et al.</i> , "Molecular Cloning -- A Laboratory Manual", Second Edition, Cold Spring Harbor Laboratory Press, TABLE OF CONTENTS (1989)	
AE9		Sanke <i>et al.</i> , "Plasma Islet Amyloid Polypeptide (Amylin) Levels and Their Responses to Oral Glucose in Type 2 (Non-Insulin-Dependent) Diabetic Patients", <u>Diabetologia</u> , 34:129-132 (1991)	
AF9		Scarpello <i>et al.</i> , "Gastric Emptying of Solid Meals in Diabetics", <u>British Medical Journal</u> , 2:671-673 (1976)	
AG9		Schvarcz <i>et al.</i> , "Hypoglycaemia Increases the Gastric Emptying Rate in Patients with Type 1 Diabetes Mellitus", <u>Diabetic Medicine</u> , 10:660-663 (1993)	
AH9		Scott and Loyd-Mostyn, "Acute Autonomic Dysfunction in Diabetic Ketoacidosis", "The Lancet", 1:590 (1976)	
AI9		Silvestre <i>et al.</i> , "Inhibitory Effect of Rat Amylin on the Insulin Responses to Glucose and Arginine in the Perfused Rat Pancreas", <u>Regulatory Peptides</u> , 31:23-31 (1990)	
AJ9		Stacher <i>et al.</i> , "Oesophageal and Gastric Motility Disorders in Patients Categorised as Having Primary Anorexia Nervosa", <u>Gut</u> , 27:1120-1126 (1986)	
AK9		Stephens <i>et al.</i> , "Presence of Liver CGRP/Amylin Receptors in Only Nonparenchymal Cells and Absence of Direct Regulation of Rat Liver Glucose Metabolism by CGRP/Amylin", <u>Diabetes</u> , 40:395-400 (1991)	
AL9		Stower <i>et al.</i> , "A Trial of Glucagon in the Treatment of Painful Biliary Tract Disease", <u>Br. J. Surg.</u> , 69:591-592 (1982)	
EXAMINER		DATE CONSIDERED	
		12/7/04	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			
* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO.	APPLICATION NO.
		18528.642	10/643,681
		APPLICANTS	
		Orville G. KOLTERMAN <i>et al.</i>	
		FILING DATE	GROUP
		August 18, 2003	<del>1646</del> 1639
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
ML	AA10	Torsdottir <i>et al.</i> , "A Small Dose of Soluble Alginate-Fiber Affects Postprandial Glycemia and Gastric Emptying in Humans with Diabetes", <u>J. Nutr.</u> , 121:795-799 (1991)	
	AB10	Wang, "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers", <u>Journal of Parenteral Science and Technical</u> , Technical Report No. 10, Supp. 42:2S (1988)	
	AC10	Wang <i>et al.</i> , "Amylin is More Potent and More Effective than Glucagon in Raising Plasma Glucose Concentration in Fasted, Anesthetized Rats", <u>Biochem. Biophys. Res. Commun.</u> , 181(3):1288-1293 (1991)	
	AD10	Wang <i>et al.</i> , " <sup>8-37</sup> h-CGRP Antagonizes Actions of Amylin on Carbohydrate Metabolism <i>In Vitro</i> and <i>In Vivo</i> ", <u>FEBS Letts.</u> , 291(2):195-198 (1991)	
	AE10	Webb <i>et al.</i> , "Glucagon and Ureteric Calculi", <u>Med. J. Aust.</u> , 144:124 (1986)	
	AF10	Woodward <i>et al.</i> , "Postgastrectomy Syndromes", <u>Surgical Clinics of North America</u> , 67(3):509-520 (1987)	
	AG10	Wright <i>et al.</i> , "Diabetic Gastroparesis: An Abnormality of Gastric Emptying of Solids", <u>Gastroenterology</u> , 84:1355 (1983)	
	AH10	Young <i>et al.</i> , "Effects of Amylin on Glucose Metabolism and Glycogenolysis <i>In Vivo</i> and <i>In Vitro</i> ", <u>Am. J. Physiol.</u> , 259:E-457-E461 (1983)	
	AI10	Young <i>et al.</i> , "Amylin Activated Glycogen Phosphorylase in the Isolated Soleus Muscle of the Rat", <u>FEBS Letts.</u> , 281(1,2):149-151 (1991)	
	AJ10	Young <i>et al.</i> , "Amylin and Insulin in Rat Soleus Muscle: Dose Responses for Cosecreted Noncompetitive Antagonists", <u>Am. J. Physiology</u> , 263(2):E274-E281 (1992)	
	AK10	Young <i>et al.</i> , " <sup>8-37</sup> h-CGRP, an Amylin Receptor Antagonist, Enhances the Insulin Response and Perturbs the Glucose Response to Infused Arginine in Anesthetized Rats", <u>Mol. Cell. Endocrinol.</u> , 84:R1-R5 (1992)	
M	AL10	Zhu <i>et al.</i> , "Amylin Increases Cyclic AMP Formation in L6 Myocytes Through Calcitonin Gene-related Peptide Receptors", <u>Biochem. Biophys. Res. Commun.</u> , 177(2):771-776 (1991)	
EXAMINER		DATE CONSIDERED	
		12/7/04	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			
* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		18528.642	10/643,681
		APPLICANTS	
		Orville G. KOLTERMAN <i>et al.</i>	
		FILING DATE	GROUP
		August 18, 2003	1646 1639
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
MI	AA11	Zierath <i>et al.</i> , "Human Islet Amyloid Polypeptide at Pharmacological Levels Inhibits Insulin and Phorbol Ester-Stimulated Glucose Transport in <i>In Vitro</i> Incubated Human Muscle Strips", <u>Diabetologia</u> , 35:26-31 (1992)	
MI	AB11	Zitomer <i>et al.</i> , "Gastric Neuropathy in Diabetes Mellitus: Clinical and Radiologic Observations", <u>Metabolism</u> , 17:199-201 (1968)	
	AC11		
	AD11		
	AE11		
	AF11		
	AG11		
	AH11		
	AI11		
	AJ11		
	AK11		
	AL11		
EXAMINER		DATE CONSIDERED	
			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			
* Copies of the listed references were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. §1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.			